Quest Diagnostics
834 hedge funds and large institutions have $14.2B invested in Quest Diagnostics in 2023 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 270 increasing their positions, 339 reducing their positions, and 94 closing their positions.
87% more call options, than puts
Call options by funds: $74.9M | Put options by funds: $40.1M
4.63% more ownership
Funds ownership: 85.17% → 89.8% (+4.6%)
5% less funds holding
Funds holding: 878 → 834 (-44)
7% less capital invested
Capital invested by funds: $15.2B → $14.2B (-$989M)
20% less repeat investments, than reductions
Existing positions increased: 270 | Existing positions reduced: 339
34% less first-time investments, than exits
New positions opened: 62 | Existing positions closed: 94
57% less funds holding in top 10
Funds holding in top 10: 7 → 3 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$273M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$198M |
| 3 |
JP Morgan Chase
New York
|
+$165M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$150M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$35.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$163M |
| 2 |
BlackRock
New York
|
-$64.5M |
| 3 |
DSA
Davis Selected Advisers
Tucson,
Arizona
|
-$45.4M |
| 4 |
Janus Henderson Group
London,
|
-$45.2M |
| 5 |
Renaissance Technologies
New York
|
-$42.4M |
DGX Hedge Fund Activity: Q1 2023 in Review
834 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Quest Diagnostics (DGX) for Q1 2023, worth a combined $14.2B — down 6.5% from $15.2B a quarter earlier.
Sellers outnumbered buyers: 94 funds closed out of DGX and 62 opened new positions — a net loss of 32 holders — while 339 trimmed existing stakes and 270 added.
The largest buyer was Wellington Management Group, adding an estimated $273M. The largest seller was T. Rowe Price Associates, cutting an estimated $163M.
- 834 institutional investors held Quest Diagnostics (DGX) as of Q1 2023, down from 878 in Q4 2022.
- Funds reported $14.2B of Quest Diagnostics stock for Q1 2023, down 6.5% quarter-over-quarter.
- 62 funds opened new Quest Diagnostics positions in Q1 2023 and 94 closed out, a net change of -32 holders.
- The largest Quest Diagnostics buyer in Q1 2023 was Wellington Management Group, an estimated $273M added.
- The largest Quest Diagnostics seller in Q1 2023 was T. Rowe Price Associates, an estimated $163M sold.
Based on aggregated 13F filings for Q1 2023.